[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610571":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":96,"collaborators":24,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":24,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":24,"enrollmentInfo":107,"targetDuration":24,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":42,"whyStopped":24,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Kivu Bioscience Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Finding","EXPERIMENTAL","Part A: KIVU-107 Dose Finding - Participants will be treated with KIVU-107 in multiple ascending cohorts.",[13],"Drug: KIVU-107",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion","Part B: KIVU-107 Dose Expansion - Participants will be treated with the RDE from Part A.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","KIVU-107","KIVU-107 will be administered IV.",[15,9],null,[26],{"name":27,"affiliation":28,"role":29},"Louie Naumovski, MD, PhD","Kivu Bioscience","STUDY_CHAIR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Kivu Bioscience (US)","CONTACT","+1.650.606.5170","KIVU10701@kivubioscience.com",{"name":37,"role":33,"phone":38,"phoneExt":24,"email":35},"Kivu Bioscience (Australia)","+61 8 7223 0122",[40,54,65,72,80,88],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":24},"Kivu Trial Site","RECRUITING","Santa Monica","California","90403","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-118.49138,34.01949,{"lat":52,"lon":51},{"facility":41,"status":42,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":64,"contacts":24},"Camperdown","New South Wales","2050","Australia","AU",{"type":49,"coordinates":61},[62,63],151.17642,-33.88965,{"lat":63,"lon":62},{"facility":41,"status":42,"city":66,"state":56,"zip":24,"country":58,"countryCode":59,"cosmosGeoPoint":67,"geoPoint":71,"contacts":24},"Sydney",{"type":49,"coordinates":68},[69,70],151.20732,-33.86785,{"lat":70,"lon":69},{"facility":41,"status":42,"city":73,"state":74,"zip":24,"country":58,"countryCode":59,"cosmosGeoPoint":75,"geoPoint":79,"contacts":24},"Brisbane","Queensland",{"type":49,"coordinates":76},[77,78],153.02809,-27.46794,{"lat":78,"lon":77},{"facility":41,"status":42,"city":81,"state":82,"zip":24,"country":58,"countryCode":59,"cosmosGeoPoint":83,"geoPoint":87,"contacts":24},"Adelaide","South Australia",{"type":49,"coordinates":84},[85,86],138.59863,-34.92866,{"lat":86,"lon":85},{"facility":41,"status":42,"city":89,"state":90,"zip":24,"country":58,"countryCode":59,"cosmosGeoPoint":91,"geoPoint":95,"contacts":24},"Geelong","Victoria",{"type":49,"coordinates":92},[93,94],144.36069,-38.14711,{"lat":94,"lon":93},{"type":97,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100610571","phase-1-a-study-of-kivu-107-in-participants-with-locally-advanced-or-metastatic-solid-tumors-100610571",false,"NCT07229313","A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors","A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Male or female ≥18 years of age\n* No therapy of proven efficacy exists for the tumor\n* Pathologically or histologically documented diagnosis of advanced \u002F metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available.\n* Adequate bone marrow, kidney, and liver function\n* Measurable disease using RECIST v1.1\n* ECOG 0 or 1\n* Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* Prior treatment with any ADC with topoisomerase 1 inhibitor payload\n* Any PTK7 - targeted therapy\n* Uncontrolled cardiovascular disease\n* Active Hepatitis B, Hepatitis C, or HIV infection\n* History of interstitial lung disease\n* Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start.","ALL","18 Years",{"count":108,"type":109},76,"ESTIMATED","INTERVENTIONAL",[112],"PHASE1","This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.",[115],"Advance Solid Tumors",[117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144],"PTK7","ADC","solid tumors","PTK-7 expression","metastatic","locally advanced","PTK7 expression","endometrial cancer","ovarian cancer","breast cancer","cervical cancer","GI\u002FGEJ adenocarcinoma","esophageal squamous cell cancer","colorectal cancer","pancreatic cancer","non-small cell lung cancer","small cell lung cancer","head and neck squamous cell carcinoma","sarcoma","OvCa","NSCLC","SCLC","CRC","PDAC","HNSCC","TNBC","triple negative breast cancer","antibody drug conjugate","2026-04-14",{"date":147,"type":148},"2026-04-16","ACTUAL",{"date":150,"type":148},"2025-11-13",{"date":152,"type":109},"2030-03-31",{"name":5,"class":6},6]